Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC

19 November 2020

Read more

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate

24 September 2020

Read more

CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach

17 September 2020

Read more

Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate

9 September 2020

Read more

CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach

9 July 2020

Read more

Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate

30 June 2020

Read more

CEBINA secures seed funding for its unique extended spectrum Coronavirus vaccine

4 June 2020

Read more

Eveliqure Biotechnologies announces regulatory approval to initiate first clinical trial of its ShigETEC vaccine candidate

2 June 2020

Read more

Calyxha Biotechnologies announces grant of a European Patent on neurodegenerative diseases

20 April 2020

Read more

CEBINA today announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus

17 April 2020

Read more

Calyxha Biotechnologies announces new financing to support pre-clinical development of its therapeutic lead candidate, CAL-X

4 March 2020

Read more

CEBINA hosted a successful launch event today at our Vienna facility

16 December 2019

Read more

Our resident company Eveliqure Biotechnologies GmbH announces a grant from the Wellcome Trust to support their effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries.

5 November 2019

https://www.eveliqure.com/news